VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds talks to Proactive's Katie Pilbeam about the strengthening of their balance, with over $33 million in cash.
Reynolds also highlights their focus on driving their commercial focus and expanding their intellectual property portfolio.
Reynolds talks through the progress on their four pillars – Nu.Q® Vet, Nu.Q Capture, NETosis and the Nu.Q technology platform.